LY2510924 inhibits proliferation of AML cells and reverses stroma-mediated chemoresistance. (A) OCI-AML3 cells (3 × 104/mL) were grown in 2% fetal bovine serum containing RPMI in the presence or absence of 100 ng/mL SDF-1α with or without daily treatment with 1 µM LY2510924 for up to 8 days. Flow cytometry using annexin V–positive/4′,6 diamidino-2-phenylindole (DAPI) –positive staining and counting beads were used to assess the percentage of apoptotic cells. (B-C) OCI-AML3 cells were cultured alone (monoculture) or cocultured with stromal cells (MS-5) as indicated in “Materials and methods.” Monocultured and cocultured cells were treated for 72 hours with 2.5 µM cytarabine (Ara-C) in the presence or absence of 1 µM LY2510924. The surface CXCR4 (B) 12G5 and (C) 1D9 staining and percentages of (D) apoptotic cells and (E) viable cells were assessed by flow cytometry. All results are expressed as the mean ± SD. *P < .05; **P < .01.
